Seres Historical Income Statement
| MCRB Stock | USD 0.77 0.04 5.48% |
Historical analysis of Seres Therapeutics income statement accounts such as Other Operating Expenses of 125.5 M can show how well Seres Therapeutics performed in making a profits. Evaluating Seres Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Seres Therapeutics's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Seres Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Seres Therapeutics is a good buy for the upcoming year.
Seres |
About Seres Income Statement Analysis
Seres Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Seres Therapeutics shareholders. The income statement also shows Seres investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Seres Therapeutics Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Seres Therapeutics. It is also known as Seres Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Seres Therapeutics financial statement analysis. It represents the amount of money remaining after all of Seres Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Net Interest Income
The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.Most accounts from Seres Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Seres Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.At present, Seres Therapeutics' Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 13.8 M, whereas Other Operating Expenses is forecasted to decline to about 125.5 M.
| 2023 | 2024 (projected) | Non Recurring | 1.3M | 1.2M | Reconciled Depreciation | 6.2M | 5.5M |
Seres Therapeutics income statement Correlations
Click cells to compare fundamentals
Seres Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Seres Therapeutics income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 9.8M | 8.9M | 9.2M | 11.9M | 15.1M | 15.9M | |
| Interest Expense | 502K | 2.9M | 2.9M | 6.0M | 13.2M | 13.8M | |
| Selling General Administrative | 24.7M | 30.8M | 69.3M | 79.7M | 87.7M | 92.1M | |
| Other Operating Expenses | 104.9M | 121.3M | 209.4M | 253.6M | 234.3M | 125.5M | |
| Operating Income | (71.9M) | (88.1M) | (64.5M) | (246.5M) | (108.0M) | (113.4M) | |
| Ebit | (78.1M) | (86.2M) | (65.9M) | (249.4M) | (100.5M) | (105.6M) | |
| Research Development | 80.1M | 90.6M | 141.9M | 172.9M | 145.9M | 87.5M | |
| Ebitda | (68.3M) | (77.3M) | (56.7M) | (237.5M) | (85.4M) | (89.7M) | |
| Total Operating Expenses | 104.9M | 121.3M | 209.4M | 253.6M | 234.3M | 125.5M | |
| Income Before Tax | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (113.7M) | (119.4M) | |
| Total Other Income Expense Net | 1.6M | (997K) | (1.1M) | (3.7M) | (5.7M) | (5.5M) | |
| Net Income | (64.2M) | (86.5M) | (61.5M) | (253.8M) | (113.7M) | (119.4M) | |
| Income Tax Expense | (6.0M) | (2.7M) | (4.1M) | 3.7M | 14.9M | 15.7M | |
| Total Revenue | 34.5M | 33.2M | 144.9M | 7.1M | 126.3M | 132.6M | |
| Net Income From Continuing Ops | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (141.3M) | (148.3M) | |
| Cost Of Revenue | 80.1M | 90.6M | 1.7M | 1.0M | 704K | 668.8K | |
| Net Income Applicable To Common Shares | (70.3M) | (89.1M) | (65.6M) | (250.2M) | (225.1M) | (213.9M) | |
| Interest Income | 1.0M | 946K | 2.9M | 3.1M | 6.7M | 7.1M | |
| Non Operating Income Net Other | 2.1M | 1.9M | 1.8M | 2.4M | 2.7M | 1.6M | |
| Net Interest Income | 531K | (2.0M) | (40K) | (3.0M) | (4.3M) | (4.1M) | |
| Reconciled Depreciation | 7.6M | 6.6M | 5.9M | 6.6M | 6.2M | 5.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Seres Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Seres Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Seres Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Seres Therapeutics Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Seres Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Seres Stock refer to our How to Trade Seres Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Seres Therapeutics. If investors know Seres will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Seres Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.40) | Revenue Per Share 0.871 | Quarterly Revenue Growth (0.93) | Return On Assets (0.1) | Return On Equity (15.56) |
The market value of Seres Therapeutics is measured differently than its book value, which is the value of Seres that is recorded on the company's balance sheet. Investors also form their own opinion of Seres Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Seres Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Seres Therapeutics' market value can be influenced by many factors that don't directly affect Seres Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Seres Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Seres Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Seres Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.